|Mr. Karim Bitar||CEO & Exec. Director||1.22M||N/A||1965|
|Mr. Stephen Wilson||Group Fin. Director & Exec. Director||788k||N/A||1960|
|Dr. Jonathan Lightner Ph.D.||Chief of R&D and Scientific Officer||N/A||N/A||N/A|
|Mr. Dan Hartley||Group Gen. Counsel & Company Sec.||N/A||N/A||N/A|
|Ms. Angelle R. Rosata SPHR||Group HR Director||N/A||N/A||N/A|
Genus plc, together with its subsidiaries, engages in the application of quantitative genetics and biotechnology for animal breeding in the porcine and bovine sectors. It operates through three segments: Genus PIC, Genus ABS, and Research and Development. The company sells sows, boars, and semen under the PIC name to breed pigs with various characteristics for pork production. It also sells bull semen and embryos that are delivered through artificial insemination to breed diary and beef cattle with various characteristics for milk and beef production under the ABS name, as well as provides various in vitro fertilization services under the IVB name. The company serves pork, beef, and dairy farmers in North America, Latin America, rest of Europe, the Middle East, Africa, and Asia. Genus plc was incorporated in 1994 and is headquartered in Basingstoke, the United Kingdom.
Genus plc’s ISS Governance QualityScore as of March 1, 2018 is 4. The pillar scores are Audit: 1; Board: 6; Shareholder Rights: 1; Compensation: 1.